Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Correspondence:
View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gaertner, S.
Right arrow Articles by Weissert, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gaertner, S.
Right arrow Articles by Weissert, R.
Related Collections
Right arrow All Immunology
Right arrow Multiple sclerosis
Right arrowRelated Article
NEUROLOGY 2004;63:2381-2383
© 2004 American Academy of Neurology
Brief Communications

Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis

Susanne Gaertner, MD, Katrien L. de Graaf, PhD, Bernhard Greve, MD and Robert Weissert, MD, PhD

From the Department of General Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, Germany.

Address correspondence and reprint requests to Dr. Robert Weissert, Experimental Neuroimmunology Laboratory, Department of General Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, Hoppe-Seyler-Strasse 3, 72076 Tübingen, Germany; e-mail: robert.weissert{at}uni-tuebingen.de

Antibodies against native glycosylated myelin-oligodendrocyte-glycoprotein (MOG) were measured by ELISA in patients with multiple sclerosis (MS) and controls. Anti-MOG IgM antibodies were elevated during the first demyelinating event. Higher MOG-specific IgG antibodies were found in patients during relapses and in secondary chronic progressive MS compared to patients in remission and healthy controls. Antibodies against native MOG may be a potential biomarker for MS.

Received February 13, 2004. Accepted in final form August 18, 2004.

See Commentary, page 2201


Related Article

December 28 Highlight and Commentary
Neurology 2004 63: 2201. [Full Text] [PDF]



This article has been cited by other articles:


Home page
 NeurologyHome page
H. Wang, K. L. Munger, M. Reindl, E. J. O'Reilly, L. I. Levin, T. Berger, and A. Ascherio
Myelin oligodendrocyte glycoprotein antibodies and multiple sclerosis in healthy young adults
Neurology, October 7, 2008; 71(15): 1142 - 1146.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. Breithaupt, B. Schafer, H. Pellkofer, R. Huber, C. Linington, and U. Jacob
Demyelinating Myelin Oligodendrocyte Glycoprotein-Specific Autoantibody Response Is Focused on One Dominant Conformational Epitope Region in Rodents
J. Immunol., July 15, 2008; 181(2): 1255 - 1263.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. Kuhle, C. Pohl, M. Mehling, G. Edan, M. S. Freedman, H.-P. Hartung, C. H. Polman, D. H. Miller, X. Montalban, F. Barkhof, et al.
Lack of Association between Antimyelin Antibodies and Progression to Multiple Sclerosis
N. Engl. J. Med., January 25, 2007; 356(4): 371 - 378.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
S J Pittock, M Reindl, S Achenbach, T Berger, W Bruck, F Konig, Y Morales, H Lassmann, S Bryant, S B Moore, et al.
Myelin oligodendrocyte glycoprotein antibodies in pathologically proven multiple sclerosis: frequency, stability and clinicopathologic correlations
Multiple Sclerosis, January 1, 2007; 13(1): 7 - 16.
[Abstract] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
P. H. Lalive, T. Menge, C. Delarasse, B. Della Gaspera, D. Pham-Dinh, P. Villoslada, H.-C. von Büdingen, and C. P. Genain
Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis
PNAS, February 14, 2006; 103(7): 2280 - 2285.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
F. Lolli, P. Rovero, M. Chelli, A. M. Papini, and R. Weissert
Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis
Neurology, September 13, 2005; 65(5): 781 - 782.
[Full Text] [PDF]

Home page
 BloodHome page
M. M. Herrmann, S. Gaertner, C. Stadelmann, J. van den Brandt, R. Boscke, W. Budach, H. M. Reichardt, and R. Weissert
Tolerance induction by bone marrow transplantation in a multiple sclerosis model
Blood, September 1, 2005; 106(5): 1875 - 1883.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
F. Lolli, B. Mulinacci, A. Carotenuto, B. Bonetti, G. Sabatino, B. Mazzanti, A. M. D'Ursi, E. Novellino, M. Pazzagli, L. Lovato, et al.
An N-glucosylated peptide detecting disease-specific autoantibodies, biomarkers of multiple sclerosis
PNAS, July 19, 2005; 102(29): 10273 - 10278.
[Abstract] [Full Text] [PDF]

Correspondence:

Read all Correspondence

Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis
Francesco Lolli, et al.
Neurology Online, 28 Mar 2005 [Full text]
Reply to Lolli et al
Robert Weissert
Neurology Online, 28 Mar 2005 [Full text]

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by AAN Enterprises, Inc.